Diagnosis of small cell lung carcinoma metastases
Cancer is defined by unscheduled cellular growth and metastatic spread into other organs of the body. Tumor cells gain their capacities form genetic alterations, also known as mutations, leading to altered protein functions and signaling pathways. Tumors are highly dependent on these oncogenic driver alterations, called oncogene addiction. Some oncogenic signaling pathways can be blocked by specific therapies. These targeted personalized therapy approaches revolutionized cancer care.
The detection of targetable oncogenic signaling pathways was significantly improved using next generation sequencing (NGS) approaches detecting somatic mutations in tumor tissue. In the daily routine clinical practice of the pathology, tissue is formalin-fixed and paraffin-embedded (FFPE) which serves for immunohistochemistry (IHC) and molecular diagnostics. Since tumor material is often limited in the clinic, multiplexed amplicon-based NGS provides a sensitive, rapid and high throughput method that can deal with low input tumor DNA. Furthermore, this method enables rapid integration of new targets into molecular routine diagnostics. Thus, broad testing for clinical trials and implementing targeted therapies can be improved.
Lung cancer causes most cancer-related deaths worldwide, whereby metastases are the predominant reason for high mortality rates. Lung cancer comprises the entities of non-small cell lung carcinomas (NSCLCs) and small cell lung carcinomas (SCLCs). Thereby, SCLC is the most aggressive form of lung cancer and is built from highly invasive neuroendocrine differentiated rapidly proliferating tumors. Tumor cells detach early from their primary tumor site in the lung and frequently translocate to distant organs such as lymph nodes, bones, the liver and the brain to induce systemic metastases and leading to an enhanced deadly outcome. Thus, it is a compulsive issue to improve SCLC diagnostics, which is routinely performed by IHC.
The main oncogenic mutations identified in SCLCs are in the RB1 gene (encoding the retinoblastoma protein, RB) and in the TP53 gene (encoding for the tumor suppressor protein 53, p53). Other recurrent mutations were found in the histone modifier genes such as CREBBP and EP300.
We investigated mutations in these SCLC related genes by amplicon-based NGS in combination with comprehensive IHC in fifty randomly collected routine cases of SCLC metastases isolated from trachea and lymph nodes. In addition, 167 cases of routinely isolated primary SCLC that were previously classified by IHC, were analyzed by amplicon-based NGS, as well.
We identified non-synchronous mutations in CREBBP and EP300 in 100% of primary SCLC and SCLC metastases. Moreover, we found frequent synchronous mutations in RB1 and TP53. Interestingly, IHC analysis revealed enhanced proliferation indicated by Ki-67 stain and a collapsed keratin cytoskeleton in SCLC lymph node metastases compared to SCLC metastases isolated from trachea.
Both features were described as being part of epithelial to mesenchymal transition (EMT) which facilitates detachment from primary tumor site and increases motility and invasion capacities of tumor cells. EMT and a collapsed keratin cytoskeleton were frequently observed in SCLCs, but this phenomenon itself was not potent enough to trigger SCLC formation or EMT induction all alone. Most likely, signaling pathways involving NOTCH mediated signaling and a central RB-p53 signaling axis are the major course of SCLC pathology.
In the future, IHC may be routinely combined with multiplexed amplicon-based NGS in SCLC diagnostics. Thereby, NGS will extensively focus on targets with therapeutic options, which remains challenging for SCLC. Members of the NOTCH- or WNT- signaling pathway may serve as relevant targets to treat SCLC patients.
Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.
Meder L, König K, Fassunke J, Ozretić L, Wolf J, Merkelbach-Bruse S, Heukamp LC, Buettner R.
Exp Mol Pathol. 2015 Dec
|How to stain E-selectin ligands in tumor tissue Cancer affects millions of people around the world. Nowadays they have more chances to survive, but still, the most frightful scenario are metastases. Few patients with metastases survive, and there…|
|Duodenal neuroendocrine tumors: what we really know… Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors and represent up to 3% of all duodenal tumors and 2–3% of all gastrointestinal tumors. Despite clear differences, dNENs have been always treated…|
|Expression of mTOR-signalling pathway proteins in… Inhibitors of the Mammalian Target of Rapamycin (mTORis) are drugs exerting both immunosuppressive and antitumor effects, and are thereby used in organ-transplant recipients (OTR) in order to both prevent allograft…|
|Role of lymphadenectomy in non-small cell lung… The prognosis and survival of non-small cell lung cancer (NSCLC) patients is dependent on the stage of disease, which is based on tumor size and nodal and distant metastasis at…|
|Adopting mammary development gameplay in breast… The process by which the breast changes during puberty and lactation is incredibly unique. Those changes are essential for the functional mammary gland. These changes are triggered and orchestrated by…|
|MS Treatment Experience at Swiss Medica: “I’ve Got… Posted by Anna Nadiryan embryologist, cell biologist, medical writer This story is told by Shaun Lawrence from the UK, who was diagnosed with relapsing-remitting multiple sclerosis in 2009. His right…|